Replies to post #589579 on NorthWest Biotherapeutics Inc (NWBO)

[Poor Man -]

Mav has a point.

The appreciation in the stock price in connection with achieving various milestones will be short lived unless the stock is listed. Over time, trading OTC will continue to rob the stock price of its intrinsic value.

My guess is NWBO will attempt to list concurrent with achieving a regulatory milestone — whether that’s acceptance of the MAA or actual approval in the UK is up in the air.

[jesster64]

Wait a minute. You can't say in one breath SP is being manipulated and then say in another breath SP reached 1.80 by itself. You also cannot use a chart if SP is being manipulated. Let's all just wait for UK approval. Real revenue, followed by other counties approval. If the company wants to remain silent, fine. It is very odd not one mention of dcvax in combo with keytruda. Not one. I keep reading Merck PR and nothing about dcvax. At this point it has to be by design since data so far suggests 50% survival. Stop with the whistleblower, lawsuit, reddit,shortsqueeze, asco, nyas, BS. Journal derisked investment. Unfortunately nwbo has done a poor job of getting that message across. Now go enjoy the weekend.

[biosectinvestor]

A BP partner accelerates things but getting approvals and having real income will change expectations immensely. As to where the stock price might be, I won't speculate, but that it could be well over a dollar, is definitely a possibility without a BP partner. Moreover, any approval is likely going to accelerate negotiations with potential partners and increase their willingness to pay more up front without worry that the bear case is somehow going to blow up in their face. This is the unfortunate impact of the AF's and their accolytes, they drive away capital intentionally, capital from retail, from institutional investors and also from BP's that might worry when they see such immense efforts to embarrass a company that it could rub off on them or be redirected at them.

I would like to see those persons held accountable at the end of the day, in some way or process. Hard to know if that will ever be the case, but I think most investors in excellent companies like NWBO often think the same thoughts after there is a success. The problem is that much graft and difficult to prosecute, mostly impossible to prosecute, crime happens in the "respectable" areas of finance and investments. The bad guys are not the entrepreneurs in a case like NWBO, but those who fleece the markets because they can get away with it. It's broad, we're not the only ones, but our long development challenges for dendritic cells, problems pioneered and made popular for shorting by DNDN, have drawn a certain element that hates to give up even when they are flat wrong. They are arrogant, almost insane with ego, and they are a problem. But the company will, I believe, beat them, and it of course was better and often is better with biotechs to get in late in the process when much of that nonsense has already mostly been done and at the lowest prices possible. That's what some of those same traders are trying to do now, in my opinion, get in, after shorting this for many years, get in or cover, at the lowest price possible before news that I think everyone, including the bears, know is likely coming, eventually.